Home › Trials › NCT03108794

Nation-wide registry for chronic Hepatitis B in China

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Observational Beijing Friendship Hospital · NCT03108794

This study is collecting information from people in China with chronic Hepatitis B to see how they are doing and improve their treatment.

Quick facts

Study typeObservational
Enrollment200000 (estimated)
SexAll
SponsorBeijing Friendship Hospital Academic / other
Locations45 sites (Beijing, Beijing and 44 other locations)
Trial IDNCT03108794 on ClinicalTrials.gov

What this trial studies

The China Registry of Hepatitis B is an observational registry that collects data on patients with chronic Hepatitis B from various hospitals across mainland China. Launched in June 2012, it records patient demographics, medical history, laboratory results, and treatment information for individuals who have been HBsAg-positive for more than six months. Patients are followed up every three to six months to monitor their clinical progress and treatment outcomes. This registry aims to enhance understanding and management of chronic Hepatitis B in the population.

Who should consider this trial

Good fit: Ideal candidates for this registry are individuals who have been HBsAg-positive for over six months, regardless of their treatment history or presence of cirrhosis.

Not a fit: Patients with hepatocellular carcinoma (HCC) may not benefit from this registry as their treatment primarily relies on surgical and interventional therapies rather than antiviral therapy.

Why it matters

Potential benefit: If successful, this registry could improve the management and treatment outcomes for patients with chronic Hepatitis B.

How similar studies have performed: Other similar registries have shown success in improving patient outcomes and understanding of chronic conditions, indicating that this approach is promising.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* HBsAg-positivity over a continuous six months.

The core exclusion criteria are: 1) HCC patients for their treatment mainly depends on surgical operation and interventional therapy, but not the antiviral therapy; 2) patients who are unable or unwilling to provide informed consent.

Where this trial is running

Beijing, Beijing and 44 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Chronic Hepatitis Bhepatitis B，registry,cirrhosis, HCC
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.